Moderna mRNA-based drug cut the risk of recurrence or death when combined with immunotherapy Keytruda
“Today’s results highlight the potential of a prolonged benefit of the intismeran autogene and Keytruda combination,” Kyle Holen,…
Merck’s Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy?
Merck shares began peeling back in early 2024, mostly on concerns about looming patent expirations for its breadwinning…